INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
FRA:IUI1 - US46120E6023 - Common Stock
405 EUR
+3.55 (+0.88%)
Overall IUI1 gets a fundamental rating of 6 out of 10. We evaluated IUI1 against 57 industry peers in the Health Care Equipment & Supplies industry. IUI1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IUI1 is valued quite expensively, but it does show have an excellent growth rating. This makes IUI1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
In the past 5 years IUI1 has always been profitable.
Each year in the past 5 years IUI1 had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 12.93%, IUI1 belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
The Return On Equity of IUI1 (14.52%) is better than 80.70% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.38%, IUI1 belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 8.81%.
The last Return On Invested Capital (10.38%) for IUI1 is above the 3 year average (9.53%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.52% | ||
| ROIC | 10.38% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
IUI1 has a Profit Margin of 28.51%. This is amongst the best in the industry. IUI1 outperforms 96.49% of its industry peers.
IUI1's Profit Margin has declined in the last couple of years.
IUI1 has a better Operating Margin (28.93%) than 98.25% of its industry peers.
In the last couple of years the Operating Margin of IUI1 has declined.
IUI1 has a better Gross Margin (66.61%) than 71.93% of its industry peers.
IUI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.93% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
IUI1 has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.17
WACC8.87%
2.3 Liquidity
IUI1 has a Current Ratio of 5.64. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.64, IUI1 belongs to the top of the industry, outperforming 98.25% of the companies in the same industry.
IUI1 has a Quick Ratio of 4.89. This indicates that IUI1 is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 4.89, IUI1 belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.64 | ||
| Quick Ratio | 4.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.97% over the past year.
The Earnings Per Share has been growing by 11.48% on average over the past years. This is quite good.
IUI1 shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.77%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
3.2 Future
Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.53% on average per year.
IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.89% yearly.
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.46%
Revenue Next 5Y14.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 58.95, IUI1 can be considered very expensive at the moment.
IUI1's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.13, IUI1 is valued quite expensively.
The Price/Forward Earnings ratio is 50.18, which means the current valuation is very expensive for IUI1.
Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than 63.16% of the companies in the same industry.
IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.76.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.95 | ||
| Fwd PE | 50.18 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than 66.67% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as IUI1.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 85.28 | ||
| EV/EBITDA | 49.85 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IUI1 may justify a higher PE ratio.
IUI1's earnings are expected to grow with 14.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.35
PEG (5Y)5.13
EPS Next 2Y13.58%
EPS Next 3Y14.55%
5. Dividend
5.1 Amount
IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IUI1 (9/1/2025, 7:00:00 PM)
405
+3.55 (+0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.73%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap145.18B
Analysts79
Price Target515.31 (27.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)-0.44%
PT rev (3m)-1.86%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-2.67%
EPS NY rev (1m)4.08%
EPS NY rev (3m)4.34%
Revenue NQ rev (1m)0.08%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)1.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.95 | ||
| Fwd PE | 50.18 | ||
| P/S | 18.6 | ||
| P/FCF | 85.28 | ||
| P/OCF | 60.18 | ||
| P/B | 9.47 | ||
| P/tB | 9.66 | ||
| EV/EBITDA | 49.85 |
EPS(TTM)6.87
EY1.7%
EPS(NY)8.07
Fwd EY1.99%
FCF(TTM)4.75
FCFY1.17%
OCF(TTM)6.73
OCFY1.66%
SpS21.78
BVpS42.75
TBVpS41.92
PEG (NY)4.35
PEG (5Y)5.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.93% | ||
| ROE | 14.52% | ||
| ROCE | 14.74% | ||
| ROIC | 10.38% | ||
| ROICexc | 22.12% | ||
| ROICexgc | 23.08% | ||
| OM | 28.93% | ||
| PM (TTM) | 28.51% | ||
| GM | 66.61% | ||
| FCFM | 21.81% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 144.66% | ||
| Cap/Sales | 9.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.74% | ||
| Profit Quality | 76.48% | ||
| Current Ratio | 5.64 | ||
| Quick Ratio | 4.89 | ||
| Altman-Z | N/A |
F-Score6
WACC8.87%
ROIC/WACC1.17
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y13.56%
EPS Next 2Y13.58%
EPS Next 3Y14.55%
EPS Next 5Y14.53%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.71%
Revenue Next 2Y17.08%
Revenue Next 3Y16.46%
Revenue Next 5Y14.89%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.31%
EBIT Next 5Y20.2%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%